Novartis's Leqvio Injection Effective at Reducing Cholesterol Longer Term
28 Agosto 2023 - 10:05AM
Dow Jones News
By Mauro Orru
Novartis said new data from a late-phase trial showed that its
Leqvio injection is effective at reducing cholesterol levels beyond
six years in patients with atherosclerotic cardiovascular
disease.
The Swiss pharmaceutical company said Monday that with
twice-yearly dosing, Leqvio, in addition to statin therapy,
provides consistent low-density lipoprotein cholesterol
reduction.
Leqvio is approved in more than 80 countries, including the
U.S.
Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94
(END) Dow Jones Newswires
August 28, 2023 08:50 ET (12:50 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024